Scilex Holding (SCLX) Current Assets (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Current Assets of $42.0 million for Q1 2026, up 46.22% year-over-year from $28.7 million in Q1 2025, and up 9.42% on a QoQ basis from $38.4 million in Q4 2025.
Scilex Holding (SCLX) Current Assets (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Current Assets for 7 consecutive years, with $42.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 46.22% year-over-year to $42.0 million; the TTM figure through Mar 2026 stood at $42.0 million (up 46.22% YoY), while the FY2025 annual figure was $38.4 million, down 7.68% from the prior year.
- Current Assets came in at $42.0 million for Q1 2026 at Scilex Holding, up from $38.4 million in the prior quarter.
- The five-year high for Current Assets was $69.2 million in Q2 2023, with the low at $165749.0 in Q3 2022.
- Average Current Assets over 5 years is $31.3 million, with a median of $33.7 million recorded in 2025.
- Across the five-year window, Current Assets jumped 15273.25% in 2023 and tumbled 58.63% in 2025, its largest moves.
- Year by year, Current Assets stood at $29.6 million in 2022, then surged by 58.0% to $46.8 million in 2023, then decreased by 11.19% to $41.5 million in 2024, then dropped by 7.68% to $38.4 million in 2025, then increased by 9.42% to $42.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $42.0 million, $38.4 million, and $16.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 54.84 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 59.17 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 41.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.97 Mn |
| Dec 31, 2025 | 38.36 Mn |
| Sep 30, 2025 | 16.49 Mn |
| Jun 30, 2025 | 33.67 Mn |
| Mar 31, 2025 | 28.70 Mn |
| Dec 31, 2024 | 41.55 Mn |
| Sep 30, 2024 | 39.86 Mn |
| Jun 30, 2024 | 50.42 Mn |
| Mar 31, 2024 | 37.75 Mn |
| Dec 31, 2023 | 46.78 Mn |
| Sep 30, 2023 | 25.48 Mn |
| Jun 30, 2023 | 69.25 Mn |
| Mar 31, 2023 | 31.10 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 165,749.00 |
| Jun 30, 2022 | 612,848.00 |
| Mar 31, 2022 | 524,341.00 |
| Dec 31, 2021 | 23.00 Mn |
| Sep 30, 2021 | 232,178.00 |
| Jun 30, 2021 | 491,980.00 |